TORONTO, Oct. 12, 2017 /CNW/ - Professor Ronald Li, CEO & Scientific Co-Founder, Novoheart Holdings Inc., joined Rob Peterman, Vice-President, Global Business Development, TMX Group, to open the market. Novoheart is a global stem cell biotechnology company dedicated to human heart engineering with offices in Vancouver, British Columbia, the United States and Hong Kong. Novoheart Holdings Inc. commenced trading on TSX Venture Exchange on October 3, 2017.
SOURCE TMX Group Limited
Share this article